Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-26T22:53:49.328Z Has data issue: false hasContentIssue false

Chapter 7 - Fetal and neonatal alloimmune thrombocytopenia

from Section 2 - Fetal disease

Published online by Cambridge University Press:  05 February 2013

By
Khadija Madani  and
Dick Oepkes
Edited by
Mark D. Kilby ,
Anthony Johnson  and
Dick Oepkes
Mark D. Kilby
Affiliation:
Department of Fetal Medicine, University of Birmingham
Anthony Johnson
Affiliation:
Baylor College of Medicine, Texas
Dick Oepkes
Affiliation:
Department of Obstetrics, Leiden University Medical Center
Get access

Summary

Introduction

Fetal thrombocytopenia is a rare but potentially devastating condition, which puts the fetus at risk of bleeding. Thrombocytopenia is commonly defined as a platelet count <150 × 109/l. However, clinically significant bleeding problems are only likely to occur with platelet counts below 50 × 109/l (although some experts set this level at ≤30 × 109/l). The most feared and indeed morbid complication is intracranial hemorrhage (ICH), often associated with perinatal death or major neurological damage as a consequence.

Many fetomaternal and neonatal conditions are associated with thrombocytopenia (Table 7.1) [1].Thrombocytopenia with an immunological origin is encountered in 0.3% of the newborns [1–3]. Fetal and neonatal alloimmune thrombocytopenia (FNAIT) and idiopathic thrombocytopenic purpura (ITP) are the most important immune-mediated thrombocytopenias.

The focus in this chapter will be on FNAIT, which is one of the major causes of both severe thrombocytopenia and ICH in fetuses and term neonates.

FNAIT is caused by maternal immunization against human platelet antigens (HPAs) on fetal platelets, inherited from the father and different from those present in the mother. The IgG alloantibodies are transported through the placenta to the fetus, and cause destruction of fetal platelets. h is disease is the platelet equivalent of red cell alloimmunization. The resulting fetal thrombocytopenia is associated with risk of bleeding complications. The most feared complication is ICH and subsequent neurological morbidity or death.

Keywords

thrombocytopenic bleedingplatelets transfusionsmaternal immunizationpregnancyintracranial hemorrhagefetal and neonatal alloimmune thrombocytopeniahuman platelet antigens
Type
Chapter
Information
Fetal Therapy
Scientific Basis and Critical Appraisal of Clinical Benefits
 , pp. 67 - 77
Publisher: Cambridge University Press
Print publication year: 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Roberts, I, Murray, NA. Neonatal thrombocytopenia: causes and management. Arch Dis Child Fetal Neonatal Ed 2003;88:F359–64.Google Scholar
Dreyfus, M, Kaplan, C, Verdy, E, et al. Frequency of immune thrombocytopenia in newborns: a prospective study. Blood 1997;89(12):4402–6.Google Scholar
Saino, S, Jarvenpaa, AL, Renlund, M, et al. Thrombocytopenia in term infants: a population-based study. Obstet Gynecol 2000;95(3):441–6.Google Scholar
Pearson, HA, Shulman, NR, Marder, VJ, Cone, TE Jr. Isoimmune neonatal thrombocytopenia. Clinical and therapeutic considerations. Blood 1964;23:154–77.Google Scholar
Kaplan, C, Morel-Kopp, MC, Kroll, H, et al. HPA-5b (Br(a)) neonatal alloimmune thrombocytopenia: clinical and immunological analysis of 39 cases. Br J Haematol 1991;78(3):425–9.Google Scholar
Mueller-Eckhardt, C, Kiefel, V, Grubert, A, et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet 1989;1(8634):363–6.Google Scholar
Durand-Zaleski, I, Schlegel, N, Blum-Boisgard, C, et al. Screening primiparous women and newborns for fetal/neonatal alloimmune thrombocytopenia: a prospective comparison of effectiveness and costs. Am J Perinatol 1996;13:423–31.Google Scholar
Porcelijn, L, Van den Akker, ES, Oepkes, D. Fetal thrombocytopenia. Semin Fetal Neonatal Med 2008;13(4):223–30.Google Scholar
Metcalfe, P, Watkins, NA, Ouwehand, WH, et al. Nomenclature of human platelet antigens. Vox Sang 2003;85(3):240–5.Google Scholar
Williamson, LM, Lubenko, A, Hadfield, R, et al. Large-scale genotyping of platelet donors for the platelet-specific alloantigens HPA-1, 2 and 3. Br J Haematol 1993;84:7.Google Scholar
Davoren, A, McParland, P, Crowley, J, et al. Antenatal screening for human platelet antigen-1a: results of a prospective study at a large maternity hospital in Ireland. BJOG 2003;110(5):492–6.Google Scholar
Kamphuis, MM, Paridaans, N, Porcelijn, L, et al. Screening in pregnancy for fetal or neonatal alloimmune thrombocytopenia: systematic review. BJOG 2010;117:1335–43.Google Scholar
L’Abbé, D, Tremblay, L, Filion, M, et al. Alloimmunization to platelet antigen HPA-1a (PIA1) is strongly associated with both HLA-DRB3*0101 and HLA-DQB1*0201. Hum Immunol 1992;34(2):107–14.Google Scholar
Bussel, JB, Primiani, A. Fetal and neonatal alloimmune thrombocytopenia: progress and ongoing debates. Blood Rev 2008;22:33–52.Google Scholar
Kjeldsen-Kragh, J, Killie, MK, Tomter, G, et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood 2007;110:833–9.Google Scholar
Williamson, LM, Hacket, G, Rennie, J, et al. The natural history of fetomaternal alloimmunization to the platelet specific antigen HPA-1a (PIAI, Zwa) as determined by antenatal screening. Blood 1998;92:2280–7.Google Scholar
Turner, ML, Bessos, H, Fagge, T, et al. Prospective epidemiologic study of the outcome and cost-effectiveness of antenatal screening to detect neonatal alloimmune thrombocytopenia due to anti-HPA-1a. Transfusion 2005;45:1945–56.Google Scholar
Davoren, A, McParland, P, Barnes, CA, Murphy, WG. Neonatal alloimmune thrombocytopenia in the Irish population: a discrepancy between observed and expected cases. J Clin Pathol 2002;55:289–92.Google Scholar
Tiller, H, Killie, MK, Skogen, B, et al. Neonatal alloimmune thrombocytopenia in Norway: poor detection rate with nonscreening versus a general screening programme. BJOG 2009;116:594–8.Google Scholar
Davoren, A, Curtis, BR, Aster, RH, et al. Human platelet antigen-specific alloantibodies implicated in 1162 cases of neonatal alloimmune thrombocytopenia. Immunohematology 2004;44:1220–5.Google Scholar
Sharif, U, Kuban, K. Prenatal intracranial hemorrhage and neurological complications in alloimmune thrombocytopenia. J Child Neurol 2001;16(11):838–42.Google Scholar
Knight, M, Pierce, M, Allen, D, et al. The incidence and outcomes of fetomaternal alloimmune thrombocytopenia: a UK national study using three data sources. Br J Haematol 2011;152:460–8.Google Scholar
Bussel, JB, Zabusky, MR, Berkowitz, RL, McFarland, JG. Fetal alloimmune thrombocytopenia. N Engl J Med 1997;337:22–6.Google Scholar
Radder, CM, Brand, A, Kanhai, HH. Will it ever be possible to balance the risk of intracranial hemorrhage in fetal or neonatal alloimmune thrombocytopenia against the risk of treatment strategies to prevent it? Vox Sang 2003;84:318–25.Google Scholar
Spencer, JA, Burrows, RF. Feto-maternal alloimmune thrombocytopenia: a literature review and statistical analysis. Aust N Z J Obstet Gynaecol 2001;41:45–55.Google Scholar
Kiefel, V, Santoso, S, Weisheit, M. Monoclonal antibody-specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet reactive antibodies. Blood 1987;70:1722–6.Google Scholar
Killie, MK, Husebekk, A, Kjeldsen-Kragh, J, Skogen, B. A prospective study of maternal anti-HPA 1a antibody level as a potential predictor of alloimmune thrombocytopenia in the newborn. Haematologica 2008;93:870–7.Google Scholar
Bertrand, C, Martageix, C, Jallu, V, et al. Predictive value of sequential anti-HPA-antibody concentrations for the severity of fetal alloimmune thrombocytopenia. J Thromb Haemost 2006;4:628–37.Google Scholar
Kjedsen-Kragh, J, Husebekk, A, Kjaer Killie, M, Skogen, B. Is it time to include screening for neonatal alloimmune thrombocytopenia in the general antenatal health program? Transfus Apher Sci 2008;38:183–8.Google Scholar
Kamphuis, MM, Oepkes, D. Fetal and neonatal autoimmune thrombocytopenia: prenatal interventions. Prenat Diagn 2011; 31(7): 712–19.Google Scholar
Daffos, F, Forestier, F, Muller, JY, et al. Prenatal treatment of alloimmune thrombocytopenia. Lancet 1984;2(8403):632.Google Scholar
Van Kamp, IL, Klumper, FJ, Oepkes, D, et al. Complications of intrauterine intravascular transfusion for fetal anemia due to maternal red-cell alloimmunization. Am J Obstet Gynecol 2005;192(1):171–7.Google Scholar
Overton, TG, Duncan, KR, Jolly, M, et al. Serial aggressive platelet transfusion for fetal alloimmune thrombocytopenia: platelet dynamics and perinatal outcome. Am J Obstet Gynecol 2002;186:826–31.Google Scholar
Giers, G, Wenzel, F, Stockschlader, M, et al. Fetal alloimmune thrombocytopenia and maternal intravenous immunoglobin infusions. Haematologica 2010;95:1921–6.Google Scholar
Birchall, JE, Murphy, MF, Kaplan, C, Kroll, H. European Fetomaternal Alloimmune Thrombocytopenia Study Group. European collaborative study of the antenatal management of feto-maternal alloimmune thrombocytopenia. Br J Haematol 2003;122:275–88.Google Scholar
Berkowitz, RL, Kolb, EA, McFarland, JG, et al. Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia. Obstet Gynecol 2006;107:91–6.Google Scholar
Sainio, S, Teramo, K, Kekomäki, R. Prenatal treatment of severe fetomaternal alloimmune thrombocytopenia. Transfus Med 1999;9:321–30.Google Scholar
Bussel, JB, Berkowitz, RL, McFarland, JG, et al. Antenatal treatment of neonatal alloimmune thrombocytopenia. N Engl J Med 1988;319:1374–8.Google Scholar
Nicolini, U, Rodeck, CH, Kochenour, NK, et al. In-utero platelet transfusion for alloimmune thrombocytopenia. Lancet 1988;2(8609):506.Google Scholar
Bussel, JB, Berkowitz, RL, Lynch, L, et al. Antenatal management of alloimmune thrombocytopenia with intravenous gamma-globulin: a randomized trial of the addition of low-dose steroid to intravenous gamma-globulin. Am J Obstet Gynecol 1996;174:1414–23.Google Scholar
Berkowitz, RL, Lesser, ML, McFarland, , et al. Antepartum treatment without early cordocentesis for standard-risk alloimmune thrombocytopenia: a randomized controlled trial. Obstet Gynecol 2007;110:249–55.Google Scholar
Van den Akker, ES, Oepkes, D, Lopriore, E, et al. Noninvasive antenatal management of fetal and neonatal alloimmune thrombocytopenia: safe and effective. BJOG 2007;114:469–73.Google Scholar
Urbaniak, SJ, Duncan, JI, Armstrong-Fisher, SS, et al. Variable inhibition of placental IgG transfer in vitro with commercial IVgG preparations. Br J Haematol 1999;107:815–17.Google Scholar
Radder, CM, Kanhai, HH, Brand, A. On the mechanism of high dose maternal intravenous immunoglobulin (IVIG) in alloimmune thrombocytopenia. In: Radder CM, Management of Fetal Alloimmune Thrombocytopenia (PhD thesis). Amsterdam: Print Partners Ipskamp. 2004; 69–81.Google Scholar
Radder, CM, de Haan, MJJ, Brand, A, et al. Follow up of children after antenatal treatment for alloimmune thrombocytopenia. Early Hum Dev 2004;80:65–76.Google Scholar
Vinograd, CA, Bussel, JB. Antenatal treatment of fetal alloimmune thrombocytopenia: a current perspective. Haematologica 2010;95:1807–11.Google Scholar
Kanhai, HH, Van den Akker, ES, Walther, FJ, Brand, A. Intravenous immunoglobulins without initial and follow-up cordocentesis in alloimmune fetal and neonatal thrombocytopenia at high risk for intracranial hemorrhage. Fetal Diagn Ther 2006;21:55–60.Google Scholar
Van Gils, JM, Stutterheim, J, van Duijn, TJ, et al. HPA-1a alloantibodies reduce endothelial cell spreading and monolayer integrity. Mol Immunol 2009;46:406–15.Google Scholar
Lynch, L, Bussel, JB, McFarland, JG, et al. Antenatal treatment of alloimmune thrombocytopenia. Obstet Gynecol 1992;80:67–71.Google Scholar
Rayment, R, Brunskill, SJ, Stanworth, S, et al. Antenatal interventions for fetomaternal alloimmune thrombocytopenia. Cochrane Database Syst Rev 2005(1):CD004226.Google Scholar
Thung, SF, Grobman, WA. The cost effectiveness of empiric intravenous immunoglobulin for the antepartum treatment of fetal and neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol 2005;193:1094–9.Google Scholar
Bussel, JB, Berkowitz, RL, Hung, C, et al. Intracranial hemorrhage in alloimmune thrombocytopenia: stratified management to prevent recurrence in the subsequent affected fetus. Am J Obstet Gynecol 2010;203:135.e1–14.Google Scholar
Kaplan, C. Platelet alloimmunity: the fetal/neonatal alloimmune thrombocytopenia. Vox Sang 2002;83:289–91.Google Scholar
Van den Akker, ES, Oepkes, D, Brand, A, Kanhai, HH. Vaginal delivery for fetuses at risk of alloimmune thrombocytopenia? BJOG 2006;113:781–3.Google Scholar
Looney, CB, Smith, JK, Merck, LH, et al. Intracranial hemorrhage in asymptomatic neonates: prevalence on MR images and relationship to obstetric and neonatal risk factors. Radiology 2007;242:535–41.Google Scholar
Rooks, VJ, Eaton, JP, Ruess, L, et al. Prevalence and evolution of intracranial hemorrhage in asymptomatic term infants. AJNR Am J Neuroradiol 2008;29:1082–9.Google Scholar
Blanchette, VS, Johnson, J, Rand, M. The management of alloimmune neonatal thrombocytopenia. Baillieres Best Pract Res Clin Haematol 2000;13(3):365–90.Google Scholar
Bussel, J, Kaplan, C, McFarland, J. Recommendations for the evaluation and treatment of neonatal autoimmune and alloimmune thrombocytopenia. The Working Party on Neonatal Immune Thrombocytopenia of the Neonatal Hemostasis Subcommittee of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 2000;65(5):631–4.Google Scholar
Bussel, JB. Alloimmune thrombocytopenia in the fetus and newborn. Semin Thromb Hemost 2001;27(3):245–52.Google Scholar
Te Pas, AB, Lopriore, E, van den Akker, ES, et al. Postnatal management of fetal and neonatal alloimmune thrombocytopenia: the role of matched platelet transfusion and IVIG. Eur J Pediatr 2007;166(10):1057–63.Google Scholar
Von Lindern, JS, van den Bruele, T, Lopriore, E, Walther, FJ. Thrombocytopenia in neonates and the risk of intraventricular hemorrhage: a retrospective cohort study. BMC Pediatr 2011;11:16.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×